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Abstract
Purpose of Review—In this review, we discuss current thinking in relation to available 
guidelines for the care of preschool-aged children with recurrent wheezing, while highlighting the 
gaps in our knowledge and discussing changes that could occur over the next 5 years.
Recent Findings—The Asthma Predictive Index (API) as well as allergen-specific IgE, 
peripheral eosinophil count, and exhaled nitric oxide are perhaps under-utilized sources of 
information that can assist in predicting progression to asthma and response to therapies. Inhaled 
corticosteroids (ICS) and leukotriene receptor antagonists (LTRA) decrease impairment and 
exacerbation frequency in wheezing children but are not disease modifying. Macrolides may be 
useful during acute wheezing episodes for preventing progression to more severe symptoms. 
Monoclonal antibodies targeting IgE and TH2 cytokines have been successful in trials of adults 
and older children with asthma, but trials in younger children are needed.
Summary—Establishing the phenotype and endotype of young wheezing children can be useful 
for prognostication of future asthma risk as well as for selection of the most appropriate treatment. 
Primary asthma prevention strategies are needed during the critical developmental window in early 
life prior to the onset of irrecoverable loss of lung function.
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Introduction
Asthma is an increasingly prevalent chronic disease among children worldwide and is 
associated with significant morbidity, mortality, and economic burden. Much research effort 
has focused on management strategies for established asthma, yet there are significant 
knowledge gaps in our understanding of young children with recurrent wheezing and 
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progression to asthma. At the 2016 AAAAILife Spectrum of Asthma meeting, workshop 
groups were asked to discuss a case of an 18-month-old child with recurrent wheezing. This 
case presented a unique opportunity to assimilate current thinking in relation to available 
guidelines with significant changes that could occur over the next 5 years.
Case presentation
An 18-month-old male child has experienced four episodes of wheezing, some severe 
enough to require evaluation in an urgent care clinic and a course of oral corticosteroids. The 
child has a positive asthma predictive index (API). How would you counsel the parents who 
want to prevent their child from developing asthma and/or more severe symptoms?
What is this child’s risk of developing asthma?
Approximately 40% of children wheeze during the first year of life, but only one-third of 
children with recurrent wheezing will have asthma in later childhood (1, 2). In this section, 
we will discuss techniques to approximate risk of progression to asthma.
The Asthma Predictive Index
Originally developed from the Tucson Children’s Respiratory Study, the Asthma Predictive 
Index (API) is a well validated tool that uses major and minor criteria to predict which 
children with early wheezing will go on to have asthma (2–5). The presence of recurrent 
wheezing in the first 3 years of life plus one major or two minorclinical criteria is considered 
positive and associated with an OR of 9.8 [5.6–17.2] for asthma at age 6 years (Table 1)(5). 
Modified versions of the API have been developed and validated and include allergen 
sensitization as a criterion that increases risk of asthma by school-age (6–8).
The Tucson Children’s Respiratory Study found that young children with persistent 
wheezing demonstrated reduced maximal expiratory flow at age 6 compared to children who 
never wheezed. A follow up of this study found that this pulmonary deficit persisted at age 
16, suggesting that the insults resulting in reduced lung function occur in the first few years 
of life (9). The appeal of the API lies in its potential to capture high-risk children during this 
critical window before development of abnormal lung function so that targeted treatment can 
be initiated. The API has high specificity and negative predictive value but low sensitivity 
and positive predictive value, and therefore it cannot be used to definitively rule out future 
asthma development or predict asthma severity (3–5, 10). Despite its limitations, the API is a 
well-validated and easily applied screening tool to evaluate asthma risk in young wheezing 
children.
Allergen-specific IgE
Allergic sensitization appears to be a key player in asthma inception (11, 12), particularly 
aeroallergen sensitization early in life (13, 14). This relationship appears to be more 
complex than simply the presence or absence of atopy, with age at onset and type and 
number of aeroallergens playing an important role in asthma risk (15). Multiple studies have 
shown a significant relationship between sensitization to multiple allergens in early life and 
Burbank and Szefler Page 2
Curr Opin Allergy Clin Immunol. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
persistent wheezing, reduced lung function, and hospital admissions for asthma (15–19). 
Additionally, allergen sensitization appears to enhance the risk of rhinovirus-induced 
wheezing, and the combination of early sensitization and viral infection increases asthma 
risk (20–22). The National Asthma Education and Prevention Program (NAEPP) suggests 
that allergy testing be considered in young children with wheezing/asthma as the results can 
provide information about asthma risk and can impact asthma control (23).
Peripheral Blood Eosinophils
Persistent eosinophilia in early childhood is associated with asthma later in life (24), and 
blood eosinophils ≥4% is included as a minor criterion in the API (5). The Tucson 
Children’s Respiratory Study found a linear relationship between blood eosinophils and 
presence of asthma across the ages of 9 months to 11 years, independent of atopy, with the 
most chronic asthma found in the group with peripheral eosinophil counts greater than 5% 
(24). Similarly children under 2 with bronchiolitis and peripheral eosinophil count of >0.45 
×109 cells/L were at increased risk of asthma at ages 7 and 12 years (25, 26). The 
Individualized Therapy for Asthma in Toddlers (INFANT) study showed that children 12–59 
months with blood eosinophils ≥ 300/µL and/or sensitization to at least one aeroallergen 
showed the most significant improvement in asthma control days and frequency of 
exacerbations when treated with daily inhaled corticosteroids (ICS) (27), suggesting that 
these biomarkers can predict steroid-responsiveness (28). Measuring peripheral eosinophilia 
may represent a minimally invasive surrogate for airway eosinophilia, though the strength of 
this correlation varies between studies and remains controversial (29, 30). Peripheral 
eosinophil count may be an under-utilized source of information that could aid in predicting 
a young wheezing child’s risk of asthma and response to treatment.
Exhaled nitric oxide (FeNO)
Elevated FeNO has been associated with eosinophilic airway inflammation in children, 
though like peripheral blood eosinophilia, the correlation between FeNO and airway 
eosinophilia is moderate and varies between studies (30–32). FeNO is increasingly used in 
both research and clinical care of asthma patients and can be performed by children as 
young as 4 years (33). FeNO level at 4 years of age is higher in persistent wheezers 
compared to transient wheezers and those who have never wheezed (34), and higher FeNO 
at age 4 is associated with greater risk of asthma at age 7 (14, 35). These findings have been 
replicated in several similar studies (36–39). Moreover, FeNO also appears to predict 
responsiveness to inhaled corticosteroids (40, 41), with higher FeNO predicting greater 
improvement in symptoms, lung function, and inflammatory markers in children with 
asthma treated with ICS compared to montelukast (28, 42). Use of FeNO in clinical practice 
is increasing and should be considered for establishing the endotype of airway disease and 
predicting steroid-responsiveness.
What interventions, if any, can impact the risk for and severity of asthma?
Guidelines for management of young wheezing children are lacking. In this section, we will 
discuss evidence-based treatment options as well as potential primary preventive strategies.
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Inhaled Corticosteroids
According to the NAEPP, ICS are the preferred long-term controller therapy in children 
regardless of age to improve symptom control and quality of life (23). Despite this 
recommendation, there is continuing debate in the field regarding the usefulness of 
corticosteroids in wheezing preschool-aged children. Some of this debate has arisen from 
studies showing a lack of efficacy of oral corticosteroids for acute wheezing episodes in this 
age group (43, 44). However, certain groups of wheezing children may be more responsive 
to corticosteroids than others, as seen in the INFANT study (27) as well as others showing 
greater response to ICS in children with higher FeNO and peripheral eosinophilia (28, 42). 
While effective for reducing impairment and exacerbations, ICS do not appear to impact loss 
of lung function over time. The Childhood Asthma Management Program (CAMP) study 
found that daily inhaled budesonide improved asthma control in 5–12 year old children but 
did not impact the degree of change in lung function over time when compared to placebo 
(45). The Prevention of Early Asthma in Kids (PEAK) trial found that daily ICS treatment in 
preschool-aged children with positive modified API was associated with fewer symptoms 
and exacerbations, but the effect was lost upon discontinuation of ICS, suggesting a lack of 
disease-modifying effects (6, 7) (Figure 1).
Most preschool-aged wheezing children experience little or no impairment between 
exacerbations, which tend to be associated with viral respiratory infections. Many clinicians 
have begun the practice of using ICS only during acute wheezing episodes or seasonally 
during fall and winter seasons when viral illnesses are most likely to occur. The 
Maintenance vs Intermittent Inhaled Steroids in Wheezing Toddlers (MIST) trial compared 
high dose ICS at the first signs of viral respiratory illness to daily ICS treatment in 
preschool-aged children with positive API but low degree of impairment (not meeting 
criteria for Step 2 asthma therapy (23, 46). The authors reported no difference between the 
groups in frequency of severe exacerbations.
While ICS is not effective for primary prevention of asthma, the evidence suggests some 
benefit in preschool-aged children with recurrent wheezing episodes. Those children who 
demonstrate elevated blood eosinophils and/or aeroallergen sensitization may benefit the 
greatest from ICS treatment. More study is needed to better characterize ICS responders and 
non-responders to allow for development of additional treatment options.
Leukotriene Receptor Antagonists
Montelukast is approved for children as young as 1 year of age and is recommended as an 
alternative to ICS when initiating controller therapy for asthma (23). Efficacy studies of 
montelukast in young children demonstrate benefit particularly in the setting of viral-
induced wheezing. The PREVIA study of children 2–5 years of age treated with montelukast 
daily for 12 months demonstrated reduction in the frequency of viral-induced exacerbations 
of asthma compared to placebo (47). Another study demonstrated reduced symptoms, need 
for rescue medications and oral corticosteroids in 2–5 year old children with asthma who 
received montelukast daily for 12 weeks (48). Children with favorable response to 
montelukast tend to be of younger age and shorter disease duration with lower FeNO, 
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peripheral eosinophilia, and serum IgE levels according to one study (28). The recently 
published INFANT trial found that many participants responded best to daily LTRA 
compared to daily or as-needed ICS but was unable to identify characteristics or biomarkers 
that predicted this response (27). Montelukast may be an appropriate first line therapy for a 
select population of preschool-aged wheezing children, but further study is needed to 
identify those most likely to have a favorable response.
Macrolides
Antibiotics are commonly prescribed during outpatient visits for wheezing, with macrolides 
being the most common (49). Macrolides are frequently prescribed for cystic fibrosis and 
COPD due to their anti-inflammatory properties and may have a role in treatment of 
recurrent wheezing and asthma as well. Bacharier et al conducted a randomized, double-
blinded trial of preschool children, half of whom had a positive modified API, using early 
administration of azithromycin 12 mg/kg for 5 days or placebo at the onset of respiratory 
illness and found a reduction in episodes of severe lower airway respiratory illness in the 
azithromycin group compared to placebo (50). Subgroup analyses found no significant effect 
of API on response to azithromycin. In an unselected Danish birth cohort, COPSAC 2010, a 
3-day course of 10 mg/kg azithromycin after the onset of respiratory illness resulted in 
significant shortening of episodes of asthma-like symptoms compared to placebo in children 
ages 1–3 (51). In a randomized placebo-controlled study of infants hospitalized with RSV 
bronchiolitis, azithromycin treatment during the episode prolonged time to the next 
wheezing episode and resulted in fewer symptomatic days over the subsequent year (52). 
Macrolides are thought to be more effective in non-eosinophilic airway inflammation, 
particularly neutrophilic inflammation associated with some types of asthma (53, 54). While 
not part of the current asthma management guidelines, macrolides could be considered for 
use during respiratory illness in preschool-aged children with wheezing to prevent 
progression to more severe symptoms.
Allergen-specific Immunotherapy
Allergen-specific subcutaneous immunotherapy (SCIT) has been shown to effectively reduce 
asthma symptoms, corticosteroid requirement, and improve quality of life, and may be one 
of the only available treatment options, apart from avoidance of tobacco smoke, for primary 
prevention of asthma in children (55–57). The European multicenter Preventive Allergy 
Treatment (PAT) study randomized children 6–14 years with allergic rhinoconjunctivitis but 
without asthma who were sensitized to birch and/or grass pollen to SCIT containing birch 
and/or grass pollen or to an open control group for 3 years. Subjects who received SCIT 
were less likely to have asthma at 2 years and 7 years after study completion than the control 
group (58–60). Sublingual immunotherapy (SLIT) trials have shown less consistent benefit 
in treatment of allergic asthma in older children, and a recent Cochrane review concluded 
that further research is needed to determine if SLIT is an effective treatment for asthma (61). 
Clinical trials in preschool aged children are needed to confirm the efficacy and safety of 
allergen-specific immunotherapy for asthma prevention.
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Anti-IgE therapy
Omalizumab is currently approved for adults and children 6 years and older with persistent 
asthma not well controlled on ICS and with sensitization to perennial allergen(s). In children 
and adolescents with allergic asthma, omalizumab resulted in decreased ICS dosage (62, 
63), frequency of asthma exacerbations (62–65), reduced rescue medication requirement 
(62), and decreased unscheduled healthcare visits (62) and hospitalizations (65). Recently 
there has been increasing interest in the use of anti-IgE therapies for primary prevention of 
asthma, presumably by preventing the cascade of inflammatory events early in life that lead 
to asthma. Studies in adults have suggested that frequent exacerbations are associated with 
more rapid decline in lung function over time (66), potentially due to repetitive injury 
leading to airway remodeling. By preventing exacerbations, omalizumab may have the 
potential to prevent irrecoverable loss of lung function, but to date this has not been studied. 
Trials of omalizumab in preschool aged children are likely on the horizon as a potential 
treatment for primary asthma prevention.
Other Anti-TH2 therapies
Additional biologics aimed at T helper cell type 2 (TH2) cytokines IL-4, 5, and 13 are 
currently under investigation for treatment of TH2-high asthma. Anti-IL-5 monoclonal 
antibody (mAb) therapy has been shown to reduce exacerbations in adults with eosinophilic 
asthma (67, 68), and clinical trials in children are ongoing. Similarly, anti-IL-4Rα therapy 
appears to reduce the frequency of asthma exacerbations and improves lung function in 
adults with eosinophilic asthma (69), but no studies have been published in children. Results 
of anti-IL-13 therapies have shown mixed results in studies of adults with asthma, with some 
showing a reduction in asthma exacerbations (70) and improved lung function (70, 71), 
while others showed no improvement in exacerbation rates and or change in asthma 
questionnaire scores (72). There are currently no active trials of anti-IL-13 mAb in children 
under 12 years. Use of anti-TH2 biologics in current practice is limited, especially among 
preschool-aged children due to a lack of evidence demonstrating efficacy and safety in this 
population. The potential use of biologics for asthma prevention or disease-modification is 
an exciting area in our field and one that is likely to dramatically change practice in the 
coming years as further clinical trials in this age group are performed.
Conclusions
While there have been many advances to our understanding of early life wheezing 
phenotypes, we are still left with many questions regarding how to best treat these young 
children. As not all children respond the same way to conventional asthma therapies, 
appropriate phenotyping and endotyping of wheezing children is essential to guide 
practitioners to the most effective therapies for management of symptoms. The bigger 
dilemma is the lack of proven treatment options for primary prevention of asthma. Allergen-
specific immunotherapy and biologics such as anti-IgE therapy will likely be further 
explored for their potential for primary prevention of asthma in certain groups of young 
children with recurrent wheezing.
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Key Points
• Insults resulting in reduced lung function occur in the first few years of life, 
so primary preventive strategies should be targeted towards very young 
children.
• The Asthma Predictive Index (API) and biomarkers such as specific IgE, 
blood eosinophils, and exhaled nitric oxide (FeNO) are useful tools to 
estimate asthma risk in young wheezing children.
• Daily ICS use in young wheezing children does not modify progression to 
asthma or prevent decline in lung function but does reduce impairment and 
exacerbations particularly in children with elevated blood eosinophils and/or 
aeroallergen sensitization.
• Allergen immunotherapy and monoclonal antibodies targeting TH2 
inflammation may represent strategies for primary prevention of allergic 
asthma, but efficacy and safety studies in young children are needed.
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Figure 1. Proportion of Episode-free Days during the Treatment Period (indicated in gray) and 
the Observation Period (indicated in white)
While fluticasone did increase the proportion of episode-free days during the treatment 
period compared to placebo, this effect was lost during the observation period after 
treatment was discontinued. The listed p-values are for comparison between the treatment 
groups during the treatment and observation periods. The vertical bars represent 95% 
confidence intervals. (From New England Journal of Medicine, Guilbert, T. et al., Long-
Term Inhaled Corticosteroids in Preschool Children at High Risk for Asthma, 354:1985-199. 
Copyright © (2006) Massachusetts Medical Society. Reprinted with permission. http://
www.nejm.org/doi/full/10.1056/NEJMoa051378.)
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Table 1
Versions of the Asthma Predictive Index
Criteria Stringent API5 Loose API5 Modified API6, 7
Wheezing Early (≤3 years) frequent 
wheezing*
Early (≤3 years) wheezing ≥4 episodes/yr during first 3 years 
of life
Major criteria
Parent with asthma Yes Yes Yes
MD-diagnosed Atopic dermatitis Yes Yes Yes
Sensitization to ≥1 aeroallergen Not included Not included Yes
Minor criteria
Wheezing unrelated to colds Yes Yes Yes
Blood eosinophils ≥4% Yes Yes Yes
MD-diagnosed Allergic rhinitis Yes Yes Not included
Sensitization to foods (milk, egg, peanut) Not included Not included Yes
For a positive API in each version, children must meet the wheezing criterion as well as at least 1 major criterion or at least 2 minor criteria.
*Score of ≥3 on scale of 1–5 for wheezing (1 = ”very rarely”, 5 = ”most days”).
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